Kenya's Kemri begins test kit mass production
This article was originally published in Clinica
Executive Summary
The Kenyan Medical Research Institute, Kemri, has started commercial production of the hepatitis B virus screening kit Kemri HepCell at dedicated new facilities in Nairobi. Kemri has been selling its kits to the ministry of health since 2002, but the decision to begin mass production marks a change in strategy and is designed meet expected growth in demand. It is predicted that Kenya will need around 400,000 HBV tests annually, and Uganda and Tanzania are also showing interest in the product. Currently, imported kits are used to bridge the demand gap not met by the Kemri HepCell kits, which cost around Ksh50 ($0.69), can conduct 200 tests per kit.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.